As of 6 Nov 2026, Kopran trades at 50.6× trailing earnings, above the industry P/E of 37.3×, and the shares are 12% below their 52-week high. Sales grew 7.2% a year over 3 years while net profit fell 1.9%, with ROCE of 7.7% and ROE of 4.9%. Debt is 0.29× equity, and its dividend yield is 1.2%. It is a small-cap company with a market cap of ₹1,265 Cr, ranked 14th of 15 Drug Manufacturers (General) companies by market cap; the shares rose 61% over the past year.
- ₹265.00
- ₹265.00
- ₹258.21
- ₹264.77
- 1.8 L
Health check
- ReturnsIn line
+61.0% over a year, better than 4 of 7 peers.
- Price tagPricier
P/E 50.6 vs industry 37.3.
- GrowthSlow
Sales +7.2%, profit −1.9% a year over 3 years.
- ProfitabilityWeak
ROCE 7.7% vs peer median 23.3%.
- Balance sheetFair
Debt 0.29× equity, interest covered 4.9×.
- Red flags3 to check
Return on equity is low at 4.9%.
Small cap
Moves with the market
Key metrics
- Market cap
- ₹1,265 Cr
- Small cap
- P/E
- 50.6
- Industry 37.3
- Price to book
- 2.38
- Peers 18.55
- Dividend yield
- 1.24%
- ROE
- 4.9%
- Peers 20.9%
- ROCE
- 7.7%
- Peers 23.3%
- Debt to equity
- 0.29
- Debt ₹153 Cr
- EPS (TTM)
- ₹5.17
- Face value ₹10
- OPM (TTM)
- 10.3%
- Net margin 3.6%
- Sales growth
- +13.9%
- Latest quarter vs a year ago
- Profit growth
- −10.0%
- Latest quarter vs a year ago
- Price to sales
- 1.81
- EV/EBITDA 17.4
Strengths and risks
Strengths
- Positive operating cash flow in each of the last 4 years.
Risks to check
- Return on equity is low at 4.9%.
- Quarterly profit down 10.0% on a year ago.
- Promoter stake down from 44.4% to 41.8%.
About Kopran
Kopran Limited, an integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, penicillin, quinolone,…
- Headquarters
- Mumbai
- Employees
- 1,156
- Sector
- Healthcare
- ISIN
- INE082A01010
- Website
- kopran.com
Price range
- Avg volume (3M)
- 10.5 L
- 1-year return
- plus 61.0%
- From 52-week high
- minus 11.5%
Peers · Drug Manufacturers - General
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GLAXOGlaxosmithkline Pharmaceuticals | 2,524.80 | plus 0.98% | 42,772 | 37.3 | 22.73 | 55.4% | 63.9% | 34.1% | 5.7% | 19.3% | 2.26% | minus 6.0% |
| RUBICONRubicon Research | 1,659.30 | minus 4.67% | 27,468 | 95.6 | 19.38 | 23.6% | 19.1% | 23.3% | – | – | 0.09% | plus 166.7% |
| PFIZERPfizer | 3,856.00 | minus 0.02% | 17,640 | 23.2 | 4.02 | 22.9% | 20.9% | 36.7% | 1.3% | 5.0% | 1.94% | minus 24.6% |
| CORONACORONA Remedies | 2,441.10 | plus 2.58% | 14,930 | 72.1 | 18.55 | 29.0% | 28.3% | 21.3% | 16.6% | 29.7% | 0.41% | plus 69.7% |
| MARKSANSMarksans Pharma | 303.70 | minus 3.20% | 13,764 | 24.6 | 4.13 | 17.5% | 15.2% | 22.5% | 16.7% | 16.2% | 0.30% | plus 68.0% |
| SYMBIOTECSymbiotec Pharmalab | 1,513.60 | plus 19.04% | 9,726 | 103.5 | 8.26 | 14.3% | 11.2% | 10.7% | 16.8% | 67.3% | 0.00% | plus 37.9% |
| SANOFICONRSanofi Consumer Healthcare India | 3,420.20 | minus 0.69% | 7,888 | 28.2 | 22.64 | – | 80.4% | 37.8% | – | – | 2.19% | minus 29.5% |
| KOPRANKopran | 261.73 | minus 1.15% | 1,265 | 50.6 | 2.38 | – | 4.7% | 6.5% | 7.2% | −1.9% | 1.24% | plus 61.0% |
| Median of 7 peers | – | −0.02% | 14,930 | 37.3 | 18.55 | 23.3% | 20.9% | 23.3% | 16.6% | 19.3% | 0.41% | 37.9% |
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| 135 | 118 | 194 | 234 | 154 | |
| 121 | 115 | 174 | 201 | 138 | |
| 14.1 | 3 | 20.2 | 33 | 15.8 | |
| 10.5% | 2.5% | 10.4% | 14.1% | 10.3% | |
| 2.6 | −8.2 | −2.4 | 0 | 2.1 | |
| 2.5 | 2.1 | 2.7 | 3.2 | 3.3 | |
| 4.3 | 4.3 | 4.4 | 4.5 | 5.8 | |
| 9.9 | −11.6 | 10.7 | 25.3 | 8.8 | |
| 24.7% | 14.6% | 13.1% | 25.6% | 23.9% | |
| 7.4 | −9.9 | 9.3 | 18.9 | 6.7 | |
| 1.54 | -2.06 | 1.93 | 3.91 | 1.39 |
Profit & loss
- Sales CAGR 3Y
- +7.2%
- Profit CAGR 3Y
- −1.9%
- EPS CAGR 3Y
- −1.9%
- ROE
- 4.9%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 548 | 615 | 624 | 676 | |
| – | +12.1% | +1.5% | +8.3% | |
| 490 | 540 | 551 | 615 | |
| 58 | 74.4 | 72.9 | 60.7 | |
| 10.6% | 12.1% | 11.7% | 9.0% | |
| −4.7 | 12.4 | 1.1 | 0.6 | |
| 4.5 | 6.4 | 7.7 | 8.8 | |
| 12.7 | 12.9 | 15.6 | 17.5 | |
| −0 | – | 1.3 | −0.6 | |
| 36.1 | 67.5 | 51.9 | 34.4 | |
| 24.5% | 24.6% | 25.8% | 25.1% | |
| 27.2 | 51 | 38.6 | 25.7 | |
| – | +87.1% | minus 24.3% | minus 33.3% | |
| 5.65 | 10.55 | 7.99 | 5.33 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 48.2 | 48.2 | 48.3 | 48.3 | |
| 391 | 443 | 470 | 482 | |
| 75.2 | 99.2 | 148 | 153 | |
| 135 | 153 | 178 | 225 | |
| 650 | 743 | 844 | 908 | |
| 227 | 259 | 296 | 344 | |
| 64.4 | 80.3 | 99.4 | 6.7 | |
| 0.1 | 0.1 | 0.1 | 0.1 | |
| 7.4 | 8.1 | 25.9 | 0.7 | |
| 351 | 395 | 423 | 557 | |
| 650 | 743 | 844 | 908 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 34 | 43.3 | 41.9 | 66.8 | |
| −12.7 | −43.6 | −56.4 | −64.6 | |
| −19.8 | 1 | 25.9 | −20.9 | |
| 1.5 | 0.7 | 11.4 | −18.8 | |
| −61 | −56.6 | −58.9 | −67.1 | |
| −27 | −13.4 | −17 | −0.4 | |
| −14.5 | −14.5 | −14.5 | −14.5 |
Shareholding pattern
- Promoters41.82%
- Public58.18%
| Quarter | Split | Promoters | Public | Promoter change |
|---|---|---|---|---|
| 30 Sep 2026 | 41.82% | 58.18% | minus 2.60 | |
| 30 Jun 2026 | 44.42% | 55.58% | 0.00 | |
| 31 Mar 2026 | 44.42% | 55.58% | 0.00 | |
| 31 Dec 2025 | 44.42% | 55.58% | 0.00 | |
| 30 Sep 2025 | 44.42% | 55.58% | – |
Major shareholders
Filings & events
News
No recent news coverage found.